Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:488331rdf:typepubmed:Citationlld:pubmed
pubmed-article:488331lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:488331lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:488331lifeskim:mentionsumls-concept:C0038699lld:lifeskim
pubmed-article:488331lifeskim:mentionsumls-concept:C1521970lld:lifeskim
pubmed-article:488331lifeskim:mentionsumls-concept:C0376315lld:lifeskim
pubmed-article:488331lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:488331pubmed:issue5lld:pubmed
pubmed-article:488331pubmed:dateCreated1979-12-18lld:pubmed
pubmed-article:488331pubmed:abstractTextComparative study of sulfamonomethoxin pharmacokinetics in the man given the drug per os or parenterally in the form of methylglucaminate showed that the latter favours higher blood concentrations of the drug 12 hours following injection. Sulfamonomethoxinmeglumin is absorbed more rapidly and has a greater bioavailability. The drug is mainly excreted with urine, more than a half being excreted in an acetylated form. It is recommended that the initial and maintenance doses be not less than 1000 and 500 mg for both dosage forms respectively. The interval between sulfanilamide administrations should not exceed 24 hours.lld:pubmed
pubmed-article:488331pubmed:languageruslld:pubmed
pubmed-article:488331pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:488331pubmed:citationSubsetIMlld:pubmed
pubmed-article:488331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:488331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:488331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:488331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:488331pubmed:statusMEDLINElld:pubmed
pubmed-article:488331pubmed:issn0014-8318lld:pubmed
pubmed-article:488331pubmed:authorpubmed-author:KivmanG IaGIalld:pubmed
pubmed-article:488331pubmed:authorpubmed-author:Ge?tmanI...lld:pubmed
pubmed-article:488331pubmed:authorpubmed-author:NeugodovaN...lld:pubmed
pubmed-article:488331pubmed:authorpubmed-author:Tse?tlinN NNNlld:pubmed
pubmed-article:488331pubmed:issnTypePrintlld:pubmed
pubmed-article:488331pubmed:volume42lld:pubmed
pubmed-article:488331pubmed:ownerNLMlld:pubmed
pubmed-article:488331pubmed:authorsCompleteYlld:pubmed
pubmed-article:488331pubmed:pagination534-7lld:pubmed
pubmed-article:488331pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:488331pubmed:meshHeadingpubmed-meshheading:488331-H...lld:pubmed
pubmed-article:488331pubmed:meshHeadingpubmed-meshheading:488331-B...lld:pubmed
pubmed-article:488331pubmed:meshHeadingpubmed-meshheading:488331-I...lld:pubmed
pubmed-article:488331pubmed:meshHeadingpubmed-meshheading:488331-A...lld:pubmed
pubmed-article:488331pubmed:meshHeadingpubmed-meshheading:488331-I...lld:pubmed
pubmed-article:488331pubmed:meshHeadingpubmed-meshheading:488331-T...lld:pubmed
pubmed-article:488331pubmed:meshHeadingpubmed-meshheading:488331-S...lld:pubmed
pubmed-article:488331pubmed:meshHeadingpubmed-meshheading:488331-K...lld:pubmed
pubmed-article:488331pubmed:meshHeadingpubmed-meshheading:488331-A...lld:pubmed
pubmed-article:488331pubmed:meshHeadingpubmed-meshheading:488331-M...lld:pubmed
pubmed-article:488331pubmed:meshHeadingpubmed-meshheading:488331-T...lld:pubmed
pubmed-article:488331pubmed:meshHeadingpubmed-meshheading:488331-P...lld:pubmed
pubmed-article:488331pubmed:meshHeadingpubmed-meshheading:488331-B...lld:pubmed
pubmed-article:488331pubmed:meshHeadingpubmed-meshheading:488331-S...lld:pubmed
pubmed-article:488331pubmed:articleTitle[Human pharmacokinetic characteristics of sulfamonomethoxine depending on the drug form].lld:pubmed
pubmed-article:488331pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:488331pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:488331pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:488331pubmed:publicationTypeEnglish Abstractlld:pubmed